Dose escalation/confirmation results of ENCORE 601, a phase Ib/II, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) Meeting Abstract
| Authors: | Johnson, M. L.; Adjei, A. A.; Opyrchal, M.; Ramalingam, S.; Janne, P. A.; Dominguez, G.; Gabrilovich, D.; de Leon, L.; Hasapidis, J.; Diede, S. J.; Ordentlich, P.; Cruickshank, S.; Meyers, M. L.; Hellmann, M. D. |
| Abstract Title: | Dose escalation/confirmation results of ENCORE 601, a phase Ib/II, open-label study of entinostat (ENT) in combination with pembrolizumab (PEMBRO) in patients with non-small cell lung cancer (NSCLC) |
| Meeting Title: | 31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016) |
| Journal Title: | Journal for ImmunoTherapy of Cancer |
| Volume: | 4 |
| Issue: | Suppl. 1 |
| Meeting Dates: | 2016 Nov 9-13 |
| Meeting Location: | National Harbor, MD |
| ISSN: | 2051-1426 |
| Publisher: | Biomed Central Ltd |
| Date Published: | 2016-11-16 |
| Start Page: | 73 |
| Language: | English |
| DOI: | 10.1186/s40425-016-0173-6 |
| PROVIDER: | manual |
| Notes: | Meeting Abstract: P215 |
